American College Of Cardiology Recommends Empagliflozin As Preferred Sglt2 Inhibitor For Adults With Type 2 Diabetes And Established Cardiovascular Disease In New Expert | Latest News RSS feed

American College Of Cardiology Recommends Empagliflozin As Preferred Sglt2 Inhibitor For Adults With Type 2 Diabetes And Established Cardiovascular Disease In New Expert - Latest News


American College of Cardiology recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 ...

A new ... by the American College of Cardiology (ACC) recommends empagliflozin as the preferred SGLT2 inhibitor for its proven benefit in reducing the risk of cardiovascular death in adults with type ... read more

ACC recommends empagliflozin as preferred SGLT2 inhibitor for adults with type 2 diabetes

A new ... American College of Cardiology (ACC) recommends Jardiance (empagliflozin) as the preferred SGLT2 inhibitor for its proven benefit in reducing the risk of cardiovascular death in adults with ... read more

Cardiology association recommends Lilly's Jardiance for lowering CV risk in type 2 diabetics

and alliance partner Boehringer Ingelheim announce that the American College of Cardiology (ACC) recommends Jardiance (empagliflozin) as the preferred SGLT2 inhibitor for reducing cardiovascular (CV) ... read more

Looking for another news?


Clear Consensus—Treat Cardiovascular Disease Concurrent with Diabetes

Clinicians caring for patients with type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD) now have more guidance in recommending the best treatment to manage both conditions. 1 The ... read more


ACC Consensus on New Diabetes Drugs to Reduce CV Outcomes

The American College of Cardiology has issued an Expert Consensus Decision Pathway aimed at educating cardiologists on the use of two major new classes of diabetes drugs — sodium-glucose cotransporter ... read more

Duke Study to Examine How Diabetes, Cardiovascular Guidelines Get Into Clinical Practice

Physicians who treat people with type 2 diabetes (T2D ... for reduction of cardiovascular event risk. ACC listed empagliflozin as the preferred SGLT2 inhibitor and liraglutide as the preferred GLP-1 ... read more

Diabetes and Lipid Management

The 2013 guidelines of the American College of Cardiology and the American Heart Association (ACC-AHA) for the treatment of cholesterol expanded the indications for statin therapy for the prevention ... read more

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes

Diabetes confers an increased risk of adverse cardiovascular and renal events. In the EMPA-REG OUTCOME trial, empagliflozin, a sodium–glucose cotransporter 2 inhibitor ... progression of kidney ... read more

Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs

Diabetes mellitus is an important risk factor for a first cardiovascular event and for worse outcomes after a cardiovascular event has occurred. Cardiovascular disease in diabetes is a progressive ... read more

ADA 2018 Standards Address Diabetes Drugs With CV Benefit

The American Diabetes Association's annual guidelines for 2018 include new recommendations for use of glucose-lowering drugs with proven cardiovascular benefit in type 2 diabetes ... statement from ... read more

Guidelines Updates in Diabetes and Cardiovascular Disease

ADA/EASD Release Joint Statement on Managing Hyperglycemia in Type 2 Diabetes ... cardiovascular disease to be treated with 1 of the 2 novel classes that have been shown to have cardiovascular ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us